Suppr超能文献

国际腹膜学会关于成人腹膜功能障碍评估的建议:分类、测量、解读和干预理由。

ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention.

机构信息

Division of Nephrology, Cliniques universitaires Saint-Luc, and Institut de Recherche Expérimentale et Clinique, 83415UCLouvain, Brussels, Belgium.

Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland.

出版信息

Perit Dial Int. 2021 Jul;41(4):352-372. doi: 10.1177/0896860820982218. Epub 2021 Feb 10.

Abstract

GUIDELINE 1: A pathophysiological classification of membrane dysfunction, which provides mechanistic links to functional characteristics, should be used when prescribing individualized dialysis or when planning modality transfer (e.g. to automated peritoneal dialysis (PD) or haemodialysis) in the context of shared and informed decision-making with the person on PD, taking individual circumstances and treatment goals into account. ().

GUIDELINE 2A: It is recommended that the PSTR is determined from a 4-h peritoneal equilibration test (PET), using either 2.5%/2.27% or 4.25%/3.86% dextrose/glucose concentration and creatinine as the index solute. () This should be done early in the course dialysis treatment (between 6 weeks and 12 weeks) () and subsequently when clinically indicated. ().

GUIDELINE 2B: A faster PSTR is associated with lower survival on PD. () This risk is in part due to the lower ultrafiltration (UF) and increased net fluid reabsorption that occurs when the PSTR is above the average value. The resulting lower net UF can be avoided by shortening glucose-based exchanges, using a polyglucose solution (icodextrin), and/or prescribing higher glucose concentrations. () Compared to glucose, use of icodextrin can translate into improved fluid status and fewer episodes of fluid overload. () Use of automated PD and icodextrin may mitigate the mortality risk associated with fast PSTR. ().

GUIDELINE 3: UF This is easy to measure and a valuable screening test. Insufficient UF should be suspected when either (a) the net UF from a 4-h PET is <400 ml (3.86% glucose/4.25% dextrose) or <100 ml (2.27% glucose /2.5% dextrose), () and/or (b) the daily UF is insufficient to maintain adequate fluid status. () Besides membrane dysfunction, low UF capacity can also result from mechanical problems, leaks or increased fluid absorption across the peritoneal membrane not explained by fast PSTR.

GUIDELINE 4A: Diagnosing intrinsic membrane dysfunction (manifesting as low osmotic conductance to glucose) as a cause of UF insufficiency: When insufficient UF is suspected, the 4-h PET should be supplemented by measurement of the sodium dip at 1 h using a 3.86% glucose/4.25% dextrose exchange for diagnostic purposes. A sodium dip ≤5 mmol/L and/or a sodium sieving ratio ≤0.03 at 1 h indicates UF insufficiency. ().

GUIDELINE 4B: in the absence of residual kidney function, this is likely to necessitate the use of hypertonic glucose exchanges and possible transfer to haemodialysis. Acquired membrane injury, especially in the context of prolonged time on treatment, should prompt discussions about the risk of encapsulating peritoneal sclerosis. ().

GUIDELINE 5: measures of peritoneal protein loss, intraperitoneal pressure and more complex tests that estimate osmotic conductance and 'lymphatic' reabsorption are not recommended for routine clinical practice but remain valuable research methods. ().

GUIDELINE 6: When resource constraints prevent the use of routine tests, consideration of membrane function should still be part of the clinical management and may be inferred from the daily UF in response to the prescription. ().

摘要

指南 1:在与 PD 患者共同做出知情决策并考虑个体情况和治疗目标的情况下,建议使用基于病理生理学的膜功能障碍分类,为个体化透析或计划转换治疗方式(例如转为自动化腹膜透析(APD)或血液透析)提供指导,这种分类方法可提供与功能特征相关的机制联系。()

指南 2A:建议使用 4 小时腹膜平衡试验(PET)来确定 PSTR,试验中使用 2.5%/2.27%或 4.25%/3.86%葡萄糖/葡萄糖浓度和肌酐作为指标溶质。()应在透析治疗开始后(6 至 12 周内)尽早进行(),并在临床需要时随后进行。()

指南 2B:PSTR 较快与 PD 患者生存率降低相关。()这种风险部分归因于 PSTR 高于平均值时发生的超滤(UF)减少和净液体再吸收增加。通过缩短基于葡萄糖的交换、使用聚葡萄糖溶液(艾考糊精)以及/或处方更高葡萄糖浓度,可以避免由此导致的净 UF 减少。()与葡萄糖相比,使用艾考糊精可以改善液体状态并减少液体超负荷发作次数。()使用 APD 和艾考糊精可能会降低与快速 PSTR 相关的死亡风险。()

指南 3:UF 这是一种易于测量的有价值的筛查试验。如果出现以下情况,应怀疑存在 UF 不足:(a) 4 小时 PET 的净 UF<400 ml(3.86%葡萄糖/4.25%葡萄糖)或 <100 ml(2.27%葡萄糖/2.5%葡萄糖),()和/或(b) 每日 UF 不足以维持充足的液体状态。()除了膜功能障碍外,UF 能力降低也可能是由于机械问题、渗漏或腹膜对液体的吸收增加所致,而这些原因无法用快速 PSTR 来解释。

指南 4A:诊断 UF 不足是由于内在膜功能障碍(表现为葡萄糖的低渗透压传导能力降低)引起:如果怀疑 UF 不足,应在 4 小时 PET 的基础上补充检测 1 小时时的钠下降情况,方法是进行 3.86%葡萄糖/4.25%葡萄糖交换,用于诊断目的。1 小时时的钠下降值≤5mmol/L 和/或钠筛系数≤0.03 表明 UF 不足。()

指南 4B:在没有残余肾功能的情况下,这可能需要使用高渗葡萄糖交换,并可能需要转为血液透析。获得性膜损伤,特别是在长期治疗的情况下,应促使讨论包裹性腹膜硬化症的风险。()

指南 5:腹膜蛋白丢失、腹腔内压力等测量方法以及更复杂的估计渗透压传导和“淋巴”再吸收的试验方法不推荐用于常规临床实践,但仍然是有价值的研究方法。()

指南 6:当资源有限无法进行常规检测时,仍应考虑膜功能,这可以从对处方的每日 UF 反应中推断出来,这也是临床管理的一部分。()

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验